Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
ABHD6 Inhibitors - Potential New Treatment for Type 2 Diabetes
AmorChem Canada flag Canada
Abstract ID:
Lipid mediators and glycerolipid/free fatty acid (GL/FFA) cycling play a key role in Glucose-Sensitive Insulin Secretion (GSIS). Modulation of ABHD6, enzyme linking GSIS to GL/FFA cycling, modulates insulin secretion in a glucose-dependent manner....
Contact John Clement
Participants
You
Email me a copy of this message

A public domain small molecule inhibitor of ABHD6 was found to inhibit the hydrolysis of MAG (the natural ligand of ABHD6), thereby reducing the levels of the most common hydrolysis products as well as increasing GSIS. Other experiments involving knockdown, knockout or overexpression of ABHD6 in islet cell and in mice confirmed its importance in controlling insulin secretion. Also, in animal models following a standard oral glucose tolerance test, the molecule enhanced insulin secretion in control mice, whereas in streptozotocin (STZ) treated mice, the compound lowered glycemia, improved glucose tolerance and restored GSIS.

The project will focus on SAR work to find ABHD6-specific inhibitors. These will then be tested in several cellular assays leading to an acute and a chronic DIO mouse model experiments.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Out-licensing or collaboration
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION